CommentBiomarkers for outcome upon MAPK inhibition in melanoma
References (10)
- et al.
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
Lancet Oncol
(2016) - et al.
Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases
Mod Pathol
(2015) - et al.
LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells
Cell Metab
(2016) - et al.
Cancer immunology. The “cancer immunogram”
Science
(2016) - et al.
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab
Clin Cancer Res
(2016)
There are more references available in the full text version of this article.
Cited by (0)
© 2016 Elsevier Ltd. All rights reserved.